Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,045 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long Term Clear all
Completed Phase 3 Interventional

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

NCT05166161
View directory record Official record
Conditions
Phenylketonuria
Interventions
PTC923
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 9:43 PM EDT
Terminated No phase listed Observational

Long Term Follow-Up Study for rAAV-GAD Treated Subjects

NCT01301573
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rAAV-GAD
Biological
Lead sponsor
Neurologix, Inc.
Industry
Eligibility
30 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 15, 2026, 9:43 PM EDT
Terminated No phase listed Observational

Assessment and Tracking of Long-term Alefacept Safety

NCT00454701
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept exposure
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Gadsden, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

NCT02175004
View directory record Official record
Conditions
FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Interventions
Inotersen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103
View directory record Official record
Conditions
Parkinson's Disease Dementia
Interventions
Rivastigmine capsule, Rivastigmine transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2011 · Synced Oct 15, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Health Outcomes of Women Veterans' Service During the Vietnam Era

NCT00958061
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Depression, Diabetes, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Female only
Enrollment
4,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Charleston, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Not applicable Interventional

An Osseointegrated Transfemoral Prosthesis Offering Long-Term Bi-Directional Efferent-Afferent Neural Transmission

NCT07615465
View directory record Official record
Conditions
Transfemoral Amputation
Interventions
MIT Powered Knee Prosthesis
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
22 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344
View directory record Official record
Conditions
Vitiligo
Interventions
ruxolitinib, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 15, 2026, 9:43 PM EDT
Not listed Phase 3 Interventional

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

NCT02652429
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 15, 2026, 9:43 PM EDT
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

NCT04877522
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
7 Years to 100 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 3 Interventional

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

NCT06208306
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
64
States / cities
Chandler, Arizona • Tucson, Arizona • La Palma, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resources to Enhance the Adjustment of Children (REACH)

NCT00820001
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Booster Treatment, No-Booster, No intervention, Treatment As Usual
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
2
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 15, 2026, 9:43 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Understanding the Long-term Impact of COVID on Children and Families

NCT05172011
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 25 Years
Enrollment
15,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 15, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound

NCT04756193
View directory record Official record
Conditions
Covid19, Echocardiography, Ultrasound
Interventions
Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Diagnostic Test
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 15, 2026, 9:43 PM EDT
Terminated Phase 4 Interventional

Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients

NCT01574131
View directory record Official record
Conditions
Second or Third Degree Burns
Interventions
Fenofibrate, Sugar Pill
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
4 Years to 20 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 15, 2026, 9:43 PM EDT
Withdrawn Not applicable Interventional

Effectiveness of Jamboxx Respiratory Therapy Device: Study 1

NCT03533400
View directory record Official record
Conditions
Spinal Cord Injuries, Respiratory Complication
Interventions
Jamboxx Respiratory Therapy Device, Jamboxx Musical Device
Device
Lead sponsor
My Music Machines Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

NCT02003144
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 15, 2026, 9:43 PM EDT
Completed No phase listed Observational

Long-term Observation of Patients With Early Rheumatoid Arthritis

NCT00240136
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 15, 2026, 9:43 PM EDT
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

NCT04684511
View directory record Official record
Conditions
Hemophilic Arthropathy
Interventions
TRM-201 (Rofecoxib), Placebo
Drug
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 15, 2026, 9:43 PM EDT
Not listed No phase listed Observational

Superficial Radiation Therapy (SRT) for the Treatment of Recurrent Keloid Scars

NCT04184011
View directory record Official record
Conditions
Keloid Scar
Interventions
SRT-100™
Device
Lead sponsor
Sensus Healthcare
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 15, 2026, 9:43 PM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01331109
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 15, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Long-term Oxygen Treatment Trial

NCT00692198
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Supplemental oxygen therapy
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 9:43 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow up of the LTOG Cohort

NCT04787822
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 15, 2026, 9:43 PM EDT